| | View this message online 
Hello manoj kumar valluru, Nice meta-analysis got published last week showing statistically significant benefit in several efficacy parameters of post-infarct patients treated with autologous stem cells. Some interesting IP was also issued. #7,514,261 covers "a culture" of bone marrow cells treated with PDGF-AB and some other cytokines as a method of generating cardiac myocytes. In our opinion simply in vitro generation is not going to be too useful because how will you actually get the cells to home to where you need them. Maybe if you can somehow "predestine" the cells in vitro to become cardiomyocytes but still have homing potential. We prefer the approach of Osiris, which was actually issued #7,514,074 covering use of mesenchymal stem cells for improvement of heart function. Apparently a different type of retinal stem cell exists that can be collected even from people that are 70 years of age! The patent #7,514,259, seems to have a interesting way in which the claims were positioned. WiCell was issued #7,514,260, covering expansion of ES cells in a media containing Noggin and FGF family members. | | Patent Number: 7,514,261 Bone marrow has been conventionally used as a source of hematopoietic stem cells for bone marrow transplant. More recently it has been shown that bone marrow can differentiate (either its hematopoietic or mesenchymal components) into various tissues including neural, hepatic and... [Read More] Ask a question OR leave your comments. | | |
Media Partnerships (NEW)
Thanks again for your help in supporting StemCellPatents.com.
Media Partnerships (NEW)
 (BETA)
------------------------------------------------------------ To unsubscribe, click here. Delivered: Tuesday April 14th, 2009 @ 14:20:38 EST | |
